News Image

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Provided By PR Newswire

Last update: Apr 10, 2024

HOLON, Israel, April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects' link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.

Read more at prnewswire.com

COMPUGEN LTD

NASDAQ:CGEN (7/22/2025, 4:04:10 PM)

1.55

+0.04 (+2.65%)



Find more stocks in the Stock Screener

Follow ChartMill for more